List of Olinvyk drug patents
Olinvyk is owned by Trevena.
Olinvyk contains Oliceridine.
Olinvyk has a total of 4 drug patents out of which 0 drug patents have expired.
Olinvyk was authorised for market use on 30 October, 2020.
Olinvyk is available in solution;intravenous dosage forms.
Olinvyk can be used as management of acute pain by intravenous injection.
Drug patent challenges can be filed against Olinvyk from October, 2024.
The generics of Olinvyk are possible to be released after 23 March, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
| US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
| US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 30, 2025 |
Drugs and Companies using OLICERIDINE ingredient
NCE-1 date: October, 2024
Market Authorisation Date: 30 October, 2020
Treatment: Management of acute pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic